Literature DB >> 28005681

Outcomes of Pulmonary Rehabilitation After Treatment for Non-Small Cell Lung Cancer Stages I to IIIa: AN OBSERVATIONAL STUDY.

Steffi M J Janssen1, Jannie J Abbink, Robert Lindeboom, Thea P M Vliet Vlieland.   

Abstract

PURPOSE: Although rehabilitation after treatment for non-small cell lung cancer (NSCLC) was found to have a beneficial effect on exercise capacity in a number of studies, insight into its effect on quality of life (QoL) and fatigue is limited. The aim of this study was to examine the outcome of pulmonary rehabilitation (PR) regarding fatigue, QoL, and exercise capacity in adult patients curatively treated for NSCLC stages I to IIIa.
METHODS: Study data were prospectively and routinely gathered in daily practice in patients taking part in an outpatient PR program after treatment for NSCLC stages I to IIIa. PR consisted of 12 weeks of supervised exercises 3 times a week, supplemented with scheduled visits with members of a multidisciplinary team. Data were gathered at initial assessment and discharge. Outcomes included fatigue (the Functional Assessment of Cancer Therapy-Fatigue and the fatigue domain of the Chronic Respiratory Disease Questionnaire); QoL (total CRQ score), Functional Assessment of Cancer Therapy-Lung, and the Short Form 36; and exercise capacity (cardiopulmonary exercise testing).
RESULTS: Fifty patients started the program out of the 70 patients referred to PR and 43 (86%) completed the program. Significant (P ≤ .01) and clinically relevant improvements were observed for all outcome measures.
CONCLUSIONS: Rehabilitation after treatment for NSCLC stages I to IIIa showed promising improvements regarding patient fatigue, QoL, and exercise capacity. PR should be considered for patients after treatment for NSCLC stages I to IIIa.

Entities:  

Mesh:

Year:  2017        PMID: 28005681     DOI: 10.1097/HCR.0000000000000227

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil Prev        ISSN: 1932-7501            Impact factor:   2.081


  6 in total

Review 1.  High-intensity exercise interventions in cancer survivors: a systematic review exploring the impact on health outcomes.

Authors:  Kellie Toohey; Kate Pumpa; Andrew McKune; Julie Cooke; Stuart Semple
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-05       Impact factor: 4.553

Review 2.  Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?

Authors:  Alice Avancini; Giulia Sartori; Anastasios Gkountakos; Miriam Casali; Ilaria Trestini; Daniela Tregnago; Emilio Bria; Lee W Jones; Michele Milella; Massimo Lanza; Sara Pilotto
Journal:  Oncologist       Date:  2019-11-26

Review 3.  The Beneficial Effects of Physical Activity in Lung Cancer Prevention and/or Treatment.

Authors:  Gaetana Messina; Nicola Tartaglia; Antonio Ambrosi; Chiara Porro; Angelo Campanozzi; Anna Valenzano; Gaetano Corso; Alfonso Fiorelli; Rita Polito; Mario Santini; Marcellino Monda; Domenico Tafuri; Giovanni Messina; Antonietta Messina; Vincenzo Monda
Journal:  Life (Basel)       Date:  2022-05-25

4.  Exercise Training in Patients With Non-Small Cell Lung Cancer During In-Hospital Chemotherapy Treatment: A RANDOMIZED CONTROLLED TRIAL.

Authors:  Anna Rutkowska; Dariusz Jastrzebski; Sebastian Rutkowski; Aleksandra Żebrowska; Arkadiusz Stanula; Jan Szczegielniak; Dariusz Ziora; Richard Casaburi
Journal:  J Cardiopulm Rehabil Prev       Date:  2019-03       Impact factor: 2.081

Review 5.  Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?

Authors:  Massimo Lanza; Sara Pilotto; Alice Avancini; Giulia Sartori; Anastasios Gkountakos; Miriam Casali; Ilaria Trestini; Daniela Tregnago; Emilio Bria; Lee W Jones; Michele Milella
Journal:  Oncologist       Date:  2019-11-26

6.  Effectiveness of Outpatient Pulmonary Rehabilitation in Patients with Surgically Resected Lung Cancer: A Retrospective Real-World Analysis.

Authors:  Oliver Illini; Arschang Valipour; Dietlinde Gattinger; Milos Petrovic; Hannah Fabikan; Maximilian Johannes Hochmair; Ralf Harun Zwick
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.